AR128689A1 - Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos - Google Patents

Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos

Info

Publication number
AR128689A1
AR128689A1 ARP230100530A ARP230100530A AR128689A1 AR 128689 A1 AR128689 A1 AR 128689A1 AR P230100530 A ARP230100530 A AR P230100530A AR P230100530 A ARP230100530 A AR P230100530A AR 128689 A1 AR128689 A1 AR 128689A1
Authority
AR
Argentina
Prior art keywords
seq
antigen
humanized
antibodies
amino acid
Prior art date
Application number
ARP230100530A
Other languages
English (en)
Inventor
Elias Quijano
Peter Glazer
Stephen Squinto
Dale Ludwig
Original Assignee
Univ Yale
Gennao Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Gennao Bio Inc filed Critical Univ Yale
Publication of AR128689A1 publication Critical patent/AR128689A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La descripción proporciona anticuerpos 3E10 humanizados y fragmentos de unión al antígeno de los mismos. También se describen las composiciones y métodos para usar los anticuerpos 3E10 humanizados y los fragmentos de unión al antígeno de los mismos para suministrar la carga. Reivindicación 1: Un anticuerpo 3E10 humanizado o fragmento de unión al antígeno del mismo que comprende un dominio variable de la cadena ligera (3E10-VL) y un dominio variable de la cadena pesada (3E10-VH), en donde: la 3E10-VL comprende una secuencia de aminoácidos que es al menos 97% idéntica a una secuencia de aminoácidos seleccionada del grupo que consiste en 3E10-VL-h1 (SEQ ID Nº 85), 3E10-VL-h2 (SEQ ID Nº 86), 3E10-VL-h3 (SEQ ID Nº 87), 3E10-VL-h4 (SEQ ID Nº 88), 3E10-VL-h5 (SEQ ID Nº 89) y 3E10-VL-h6 (SEQ ID Nº 90), y la 3E10-VH comprende una secuencia de aminoácidos que es al menos 95% idéntica a una secuencia de aminoácidos seleccionada del grupo que consiste en 3E10-VH-h1 (SEQ ID Nº 64), 3E10-VH-h2 (SEQ ID Nº 65), 3E10-VH-h3 (SEQ ID Nº 66), 3E10-VH-h4 (SEQ ID Nº 67), 3E10-VH-h5 (SEQ ID Nº 68), 3E10- VH-h6 (SEQ ID Nº 69) y 3E10-VH-h7 (SEQ ID Nº 70). Reivindicación 78: Una composición que comprende un complejo no covalente de: (i) un anticuerpo 3E10 humanizado o fragmento de unión al antígeno del mismo de acuerdo con una cualquiera de las reivindicaciones 1 - 77 y (ii) un polinucleótido. Reivindicación 158: Un polinucleótido que codifica el anticuerpo 3E10 humanizado o fragmento de unión al antígeno del mismo de acuerdo con una cualquiera de las reivindicaciones 1 - 77. Reivindicación 159: Una célula hospedera que alberga la composición de polinucleótido de acuerdo con la reivindicación 158.
ARP230100530A 2022-03-03 2023-03-02 Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos AR128689A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263316338P 2022-03-03 2022-03-03

Publications (1)

Publication Number Publication Date
AR128689A1 true AR128689A1 (es) 2024-06-05

Family

ID=85772764

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100530A AR128689A1 (es) 2022-03-03 2023-03-02 Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos

Country Status (4)

Country Link
US (1) US20230303719A1 (es)
AR (1) AR128689A1 (es)
TW (1) TW202346364A (es)
WO (1) WO2023168352A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024145398A1 (en) 2022-12-27 2024-07-04 Yale University Antibody drug conjugates

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
WO1989007142A1 (en) 1988-02-05 1989-08-10 Morrison Sherie L Domain-modified constant region antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
AU707440B2 (en) 1994-03-29 1999-07-08 Celltech Therapeutics Limited Antibodies against E-selectin
AU709503B2 (en) 1996-03-08 1999-09-02 Regents Of The University Of California, The Delivery system using mAb 3E10 and mutants and/or functional fragments thereof
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CA2527878A1 (en) 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
EP1664116A4 (en) 2003-08-22 2009-06-03 Biogen Idec Inc IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
PT2176408E (pt) 2008-01-31 2015-04-23 Curevac Gmbh Ácidos nucleicos compreendendo a fórmula (nuglxmgnnv)a e os seus derivados como agentes/adjuvantes imunoestimuladores
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2010002851A1 (en) 2008-06-30 2010-01-07 Alnylam Pharmaceuticals, Inc. Silencing and rig-1 activation by dual function oligonucleotides
ME02568B (me) 2009-11-30 2017-02-20 Janssen Biotech Inc MUTIRANA Fc ANTITELA SA UKLONJENOM EFEKTORSKOM FUNKCIJOM
CA2799595C (en) 2010-05-27 2022-08-16 Merck Sharp & Dohme Corp. Method for preparing antibodies having improved properties
CA2828289C (en) 2011-03-29 2020-07-21 Roche Glycart Ag Antibody fc variants
EP2773760B2 (en) 2011-10-31 2020-11-04 RiboxX GmbH Double-stranded rna for immunostimulation
US9283272B2 (en) 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9861574B2 (en) 2013-04-09 2018-01-09 Duke University 2-fluoro-modified RNAs as immunostimulators
US9775894B2 (en) 2013-07-09 2017-10-03 University Of Washington Through Its Center For Commercialization Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling
JP6709733B2 (ja) * 2014-01-13 2020-06-17 バレリオン セラピューティクス， エルエルシー 内在化部分
EP3194450A1 (en) 2014-08-28 2017-07-26 Yale University Multivalent fragments of antibody 3e10 and methods of use thereof
DE102015008536A1 (de) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
WO2017079369A2 (en) 2015-11-03 2017-05-11 Glaxosmithkline Llc Novel antibodies
KR20220143151A (ko) 2016-04-01 2022-10-24 바이셀릭스, 인크. 신규 rna 구축물 및 세포독성 세포 및 줄기 세포의 치료 효과를 증진시키기 위한 그의 사용 방법
US11590242B2 (en) 2016-06-15 2023-02-28 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
CN109790216A (zh) 2016-10-06 2019-05-21 葛兰素史克知识产权开发有限公司 与工艺杂质的结合降低的抗体
JP7062669B2 (ja) 2016-12-23 2022-05-06 ブリストル－マイヤーズ スクイブ カンパニー 改善されたバイオアナリシス特性およびバイオプロセシング特性のための、治療用免疫グロブリンｇ４の設計
EP3600342B1 (en) 2017-03-24 2021-06-23 Rigontec GmbH Method for designing rig-i ligands
EP3655432A4 (en) * 2017-07-17 2021-04-14 Nucleus Therapeutics Pty Ltd BINDING PROTEIN 1
EP3740577A4 (en) 2018-01-17 2021-10-20 Nanyang Technological University SMALL RNA MOLECULES IN IMMUNOMODULATOR HAIRPIN
WO2019152808A1 (en) 2018-02-01 2019-08-08 Yale University Compositions and methods for inhibition of nuclear-penetrating antibodies
US20210054102A1 (en) 2018-02-01 2021-02-25 Yale University Compositions and methods for enhancing nuclear translocation
AU2019215191A1 (en) 2018-02-02 2020-09-17 University Of Washington Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling
CA3093715A1 (en) 2018-04-19 2019-10-24 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
CN112672748A (zh) 2018-06-20 2021-04-16 耶鲁大学 Rig-i激动剂以及使用其的治疗
SG11202101984PA (en) 2018-08-31 2021-03-30 Univ Yale Compositions and methods for enhancing triplex and nuclease-based gene editing
US20210340280A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
WO2020260547A1 (en) 2019-06-27 2020-12-30 Rigontec Gmbh Design method for optimized rig-i ligands
WO2021076713A1 (en) 2019-10-16 2021-04-22 Somalogic, Inc. Nucleic acid compounds that bind to retinoic acid-inducible gene i protein
WO2023278897A1 (en) 2021-07-02 2023-01-05 Yale University Compositions and methods for treating cancers

Also Published As

Publication number Publication date
US20230303719A1 (en) 2023-09-28
TW202346364A (zh) 2023-12-01
WO2023168352A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
AR110979A1 (es) Moléculas de unión a cd70 y métodos de uso de las mismas
AR126242A2 (es) Tratamiento del cáncer utilizando receptores de antígenos quiméricos
AR128689A1 (es) Anticuerpos 3e10 humanizados, variantes y fragmentos de unión al antígeno de los mismos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR112257A1 (es) Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
AR109264A1 (es) Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
BR112018072140A2 (pt) anticorpos anti-basigin humanizados e uso dos mesmos
PE20230385A1 (es) Anticuerpos anti-phf-tau y usos de estos
PE20231078A1 (es) Anticuerpos anti-tigit
AR110755A1 (es) Anticuerpos dirigidos a hueso
AR124084A1 (es) ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO
PE20220763A1 (es) Materiales y metodos para modular la inmunidad mediada por celulas t
RU2011104709A (ru) Фармацевтическая композиция для лечения и предупреждения рака
EA202192508A1 (ru) Способы получения композиций антитела к фно
AR083971A1 (es) Anticuerpos antiproliferacion humanizados homogeneos
AR128688A1 (es) Anticuerpos anti-cd39 y uso de los mismos
AR127271A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
AR126154A1 (es) Agentes aglutinantes biespecíficos que se unen a cldn18.2 y cd3
AR125488A1 (es) Proteínas de unión biespecíficas de pd-1 y de tigit, y usos de las mismas
AR127273A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos
AR126578A1 (es) Anticuerpos anti-ccr8
AR116937A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
PE20231093A1 (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
EA202192505A1 (ru) Способы получения композиций антитела к фно